The results of preclinical and clinical studies obtained with NGR-TNF indicate that extremely low doses of this drug (e.g., 100 pg/mouse or 0.8 μg/m2 in patients) are sufficient to affect the tumor vasculature and to induce anti-tumor effects. Here, TNF is linked to neoplasm.